RGDV is a tetrapeptide that delivers attached compounds to targets such as thrombus or tumor cells; it enhances efficacy of anticancer and anti-aggregation or anti-adhesion compounds. RGDV binds integrins on the surfaces of cells and prevents binding of fibrinogen to platelets.

References


Preferred conformations of RGDX tetrapeptides to inhibit the binding of fibrinogen to platelets.